Is urotensin-II the new endothelin?

British Journal of Pharmacology

Volumn 137, Issue 5, 2002, Pages 579-588

  Maguire, Janet J ^a   Davenport, Anthony P ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

GPR14; Orphan receptor; SENR; Urotensin II; UT II; Vasoconstriction; Vasodilatation

Indexed keywords

ENDOTHELIN; G PROTEIN COUPLED RECEPTOR; ORPHAN RECEPTOR; SENSORY EPITHELIUM NEUROPEPTIDE LIKE RECEPTOR; UNCLASSIFIED DRUG; UROTENSIN II;

AMINO ACID SEQUENCE; ARTERY; ATHEROSCLEROSIS; BLOOD FLOW; BRONCHUS MUSCLE; CENTRAL NERVOUS SYSTEM; HEART FAILURE; HEART HYPERTROPHY; HUMAN; INOTROPISM; MICROCIRCULATION; MONKEY; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; PULMONARY HYPERTENSION; RAT; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE; STRUCTURE ACTIVITY RELATION; TELEOST; TUMOR GROWTH; VASCULAR TISSUE; VASOCONSTRICTION; VASODILATATION;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELINS; HUMANS; SEQUENCE HOMOLOGY, AMINO ACID; UROTENSINS;

EID: 0036848062     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0704924     Document Type: Review

References (71)

1. Ames, R.S., Sarau, H.M., Chambers, J.K., Willette, R.N., Alyar, N.V., Romanic, A.M., Louden, C.S., Foley, J.J., Sauermelch, C.F., Coatney, R.W., Ao, Z., Disa, J., Holmes, S.D., Stadel, J.M., Martin, J.D., Liu, W.-S., Glover, G.I., Wilson, S., McNulty, D.E., Ellis, C.E., Elshourbagy, N.A., Shabon, U., Trill, J.J., Hay, D.W.P., Olstein, E.H., Bergsma, D.J. & Douglas, S.A. (1999). Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature, 401, 282-286.
2. Asham, E., Shankar, A., Loizidou, M., Fredericks, S., Miller, K., Boulos, P.B., Burnstock, G. & Taylor, I. (2001). Increased endothelin-1 in colorectal cancer and reduction of tumour growth by ET(A) receptor antagonism. Br. J. Cancer, 85, 1759-1763.
3. Bacon, C.R., Cary, N.R.B. & Davenport, A.P. (1996). Endothelin peptides and receptors in human atherosclerotic coronary artery and aorta. Circ. Res., 79, 794-801.
4. Bern, H.A., Pearson, D., Larson, B.A. & Nishioka, R.S. (1995). Neurohormones from fish tails: The caudal neurosecretory system. I. "Urophysiology" and the caudal neurosecretory system of fishes. Recent Prog. Hormone Res., 41, 533-552.
5. Böhm, F. & Pernow, J. (2002). Urotensin II evokes potent vasoconstriction in humans in vivo. Br. J. Pharmacol., 135, 25-27.
6. Bottrill, F.E., Douglas, S.A., Hiley, C.R. & White, R. (2000). Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br. J. Pharmacol., 130, 1865-1870.
7. Burrell, K.M., Molenaar, P., Dawaon, P.J. & Kaumann, A.J. (2000). Contractile and arrhythmic effects of endothelin receptor agonists in human heart in vitro: Blockade with SB 209670. J. Pharmacol. Exp. Therap., 292, 449-459.
8. Chartrel, N., Conlon, J.M., Collin, F., Braun, B., Waugh, D., Vallarino, M., Lachrichi, S.L., Rivier, J.E. & Vaudry, H. (1996). Urotensin II in the central system of the frog Rana ridibunda: Immunohistochemical localization and biochemical characterization. J. Camp. Neurol., 364, 324-339.
9. Clark, S.D., Nothacker, H.-P., Wang, Z., Saito, Y., Leslie, F.M. & Civelli, O. (2001). The urotensin II receptor is expressed in the cholinergic mesopontine tegmentum of the rat. Brain Res., 923, 120-127.
10. Clarke, J.G., Benjamin, N., Larkin, S.W., Webb, D.J., Davies, G.J. & Maseri, A. (1989). Endothelin is a potent long-lasting vasoconstrictor in men. Am. J. Physiol., 257, H2033-H2035.
11. Coulouarn, Y., Fernex, C., Jegou, S., Henderson, C.E., Vaudry, H. & Lihrmann, I. (2001). Specific expression of the urotensin II gene in sacral motoneurons of developing rat spinal cord. Mech. Develop., 101, 187-190.
12. Coulouarn, Y., Jegou, S., Tostivint, H., Vaudry, H. & Lihrmann, I. (1999). Cloning, sequence analysis and tissue distribution of the mouse and rat urotensin II precursors. FEBS Lett., 457, 28-32.
13. Coulouarn, Y., lihrmann, I., Jegou, S., Anouar, Y., Tostivint, H., Beauvillain, J.-C., Conlon, J.M., Bern, H.A. & Vaudry, H. (1998). Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc. Natl. Acad. Sci., 95, 15803-15808.
14. Davenport, A.P. & Maguire, J.J. (2000). Urotensin II: Fish neuropeptide catches orphan receptor. Trends Pharmacol. Sci., 21, 80-82.
15. A sub-type. Br. J. Pharmacol., 114, 1110-1116.
16. Douglas, S.A., Ashton, D.J., Sauermelch, C.F., Coatney, R.W., Ohlstein, D.H., Ruffolo, M.R., Ohlstein, E.H., Aiyar, N.V. & Willette, R.N. (2000a). Human urotensin-II is a potent vasoactive peptide: Pharmacological characterization in rat, mouse, dog and primate. J. Cardiovasc. Pharmacol., 36(Suppl. 1): S163-S166.
17. Douglas, S.A. & Ohlstein, E.H. (2000). Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc. Med., 10, 229-237.
18. Douglas, S.A., Sulpizio, A.C., Piercy, V., Sarau, H.M., Ames, R.S., Aiyar, N.V., Ohlstein, E.H. & Willette, R.N. (2000b). Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br. J. Pharmacol., 131, 1262-1274.
19. Dschietzig, T., Richter, C., Bartsch, C., Bohme, C., Heinze, D., Ott, F., Zartnack, F., Baumann, G. & Stangl, K. (2001). Flow-induced pressure differentially regulates endothelin-1, urotensin-II, adrenomedullin, and relaxin in pulmonary vascular endothelium. Biochem. Biophys. Res. Commun., 289, 245-251.
20. Dun, S.L., Brailoiu, G.C., Yang, J., Chang, J.K. & Dun, N.J. (2001). Urotensin II-immunoreactivity in the brainstem and spinal cord of the rat, Neurosci. Letts., 305, 9-12.
21. Gardiner, S.M., March, J.E., Kemp, P.A., Davenport, A.P. & Bennet, T. (2001). Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats. Br. J. Pharmacol., 132, 1625-1629.
22. Gartlon, J., Parker, F., Harrison, D.C., Douglas, S.A., Ashmeade, T.E., Riley, G.J., Hughes, Z.A., Taylor, S.G., Munton, R.P., Hagan, J.J., Hunter, J.A. & Jones, D.N.C. (2001). Central effects of urotensin-II following ICV administration in rats. Psychopharmacology, 155, 426-433.
23. Gibson, A. (1987). Complex effects of Gillichthys urotensin II on rat aortic strips. Br. J. Pharmacol., 91, 205-212.
24. Gibson, A., Bern, H.A., Ginsburg, M. & Botting, J.H. (1984). Neuropeptide-induced contraction and relaxation of the mouse anococcygeus muscle. Proc. Natl. Acad. Sci., 81, 625-629.
25. Gibson, A., Conyers, S. & Bern, H.A. (1988). The influence of urotensin-II on calcium flux in rat aorta. J. Pharm. Pharmacol., 40, 893-895.
26. Gibson, A., Wallace, P. & Bern, H.A. (1986). Cardiovascular effects of urotensin-II in anesthetized and pithed rats. Gen. Comp. Endocrinol., 64, 435-439.
27. Gray, G.A., Jones, M.R. & Sharif, I. (2001). Human urotensin-II increases coronary perfusion pressure in the isolated rat heart. Potentiation by nitric oxide synthase and cyclo-oxygenase inhibition. Life Sci., 69, 175-180.
28. Hasegawa, K., Kobayashi, Y. & Kobayashi, H. (1992). Vasodepressor effects of urotensin-II in rats. Neuroendocrinol. Lett., 14, 357-363.
29. Hay, D.W.P., Luttmann, M.A. & Douglas, S.A. (2000). Human urotensin-II is a potent spasmogen of primate airway smooth muscle. Br. J. Pharmacol., 131, 10-12.
30. Haynes, W.G. & Webb, D.J. (1994). Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet, 344, 852-854.
31. Heller, J., Schepke, M., Neef, M., Woitas, R.P. & Sauerbruch, T. (2001). Increased urotensin II plasma levels in patients with cirrhosis. J. Hepatology, 34 (Suppl. 1): 18-19.
32. Hillier, C., Berry, C., Petrie, M.C., O'Dwyer, P.J., Hamilton, C., Brown, A. & McMurray, J. (2001). Effects of urotensin-II in human arteries and veins of varying calibre. Circulation, 103, 1378-1381.
33. Huggins, J.P., Pelton, J.T. & Miller, R.C. (1993). The structure and specificity of endothelin receptors: Their importance in physiology and medicine. Pharmacol. Ther., 59, 55-123.
34. Ide, K., Yamakawa, K., Nakagomi, T., Sasaki, T., Saito, I., Kurihara, H., Yosizumi, M., Yazaki, Y. & Takakura, K. (1989). The role of endothelin in the pathogenesis of vasospasm following subarachnoid haemorrhage. Neurol. Res., 11, 101-104.
35. Itoh, H., Itoh, Y., River, J. & Lederis, K. (1987). Contraction of major artery segments of rat by fish neuropeptide urotensin II. Am. J. Physiol., 252, R361-R366.
36. Itoh, H., McMaster, D. & Lederis, K. (1988). Functional receptors for fish neuropeptide urotensin II in major rat arteries. Eur. J. Pharmacol., 149, 61-66.
37. Katano, Y., Ishihata, A., Aita, T., Ogaki, T. & Horie, T. (2000). Vasodilator effect of urotensin II, one of the most potent vasoconstricting factors, on rat coronary arteries. Eur. J. Pharmacol., 402, 209-211.
38. 1 receptor antagonist losartan. Br. J. Pharmacol., 134, 1385-1392.
39. Kedzierski, R.M. & Yanagisawa, M. (2001). Endothelin system: The double-edged sword in health and disease. Annual Rev. Pharmacol. Toxicol., 41, 851-876.
40. Kuc, R.E., Maguire, J.J. & Davenport, A.P. (2001). Urotensin-II is a potent constrictor of human atherosclerotic coronary arteries with immunoreactive peptide localised to the atherosclerotic plaque. Br. J. Pharmacol., 134, 75.
41. Leslie, S.J., Denvir, M. & Webb, D.J. (2001). Human urotensin II causes vasoconstriction in the human skin microcirculation. Circulation, 102(Suppl. II): 542.
42. Liu, Q., Pong, S.-S., Zeng, Z., Zhang, Q., Howard, A.D., Williams Jr., D.L., Davidoff, M., Wang, R., Austin, C.P., McDonald, T.P., Bai, C., George, S.R., Evans, J.F. & Caskey, C.T. (1999). Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. Biochem. Biophys. Res. Commun., 266, 174-178.
43. Maclean, M.R., Alexander, D., Stirrat, A., Gallagher, M., Douglas, S.A., Ohlstein, E.H., Morecroft, I. & Polland, K. (2000). Contractile responses to human urotensin-II in rat and human pulmonary arteries: Effect of endothelial factors and chronic hypoxia in rat. Br. J. Pharmacol., 130, 201-204.
44. Maguire, J.J., Kuc, R.E. & Davenport, A.P. (2000). Orphan-receptor ligand human urotensin II: Receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br. J. Pharmacol., 131, 441-446.
45. Marchese, A., Heiber, M., Nguyen, T., Heng, H.H.Q., Saldiva, V.R., Cheng, R., Murphy, P.M., Tsui, L.-C., Shi, X., Gregor, P., George, S., O'Dowd, B.F. & Docherty, J.M. (1995). Cloning and chromosomal mapping of three novel genes, GPR9, GPR10 and GPR14, encoding receptors related to interleukin 8, neuropeptide Y and somatostatin receptors. Genomics, 29, 335-344.
46. Matsushita, M., Shichiri, M., Imai, T., Iwashina, M., Tanaka, H., Takasu, N. & Hirata, Y. (2001). Co-expression of urotensin-II and its receptor (GPR14) in human cardiovascular and renal tissues. J. Hypertens., 19, 2185-2190.
47. Miyauchi, T. & Goto, K. (1999). Heart failure and endothelin receptor antagonists. Trends Pharmacol. Sci., 20, 210-217.
48. Miyauchi, T. & Masaki, T. (1999). Pathophysiology of endothelin in the cardiovascular system. Ann. Rev. Physiol., 61, 391-415.
49. Mori, M., Sugo, T., Abe, M., Shimomura, Y., Kurihara, M., Kitada, C., Kikuchi, K., Shintani, Y., Kurokawa, T., Onda, H., Nishimura, O. & Fujino, M. (1999). Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14). Biochem. Biophys. Res. Commun., 265, 123-129.
50. Nelson, J.B. (2001). Endothelin receptor antagonists in the treatment of prostate cancer. Prostate, 49, 91-92.
51. Nothacker, H.-P., Wang, Z., McNeill, A.M., Saito, Y., Merten, S., O'Dowd, B., Duckles, S.P. & Civelli, O. (1999). Identification of the natural ligand of an orphan receptor G-protein-coupled receptor involved in the regulation of vasoconstriction. Nature Cell Biol., 1, 383-385.
52. Pearson, D., Shively, J.E., Clark, B.R., Geschwind, I.I., Barkley, M., Nishioka, R.S. & Bern, H.A. (1980). Urotensin II: A somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc. Natl. Acad. Sci., 77, 5021-5024.
53. Pernow, J., Hemsen, A., Lundberg, J.M., Nowak, J. & Kaijser, L. (1991). Potent vasoconstrictor effects and clearance of endothelin in the human forearm. Acta Physiol. Scand., 141, 319-324.
54. Protopopov, A., Kashuba, V., Podowski, R., Gizatullin, R., Sonnhammer, E., Wahlestedt, C. & Zabarovsky, E.R. (2000). Assignment of the GPR14 gene coding for the G-protein-coupled receptor 14 to human chromosome 17q25.3 by fluorescent in situ hybridization. Cytogenet. Cell Genet., 88, 312-313.
55. Russell, F.D. & Davenport, A.P. (1999). Secretory pathways in endothelin synthesis. Br. J. Pharmacol., 126, 391-398.
56. Russell, F.D., Molenaar, P. & O'Brien, D.M. (2001). Cardiostimulant effects of urotensin-II in human heart in vitro. Br. J. Pharmacol., 132, 5-9.
57. Saetrum Opgaard, O., Nothacker, H.-P., Ehlert, F.J. & Krause, D.N. (2000). Human urotensin II mediates vasoconstriction via an increase in inositol phosphates. Eur. J. Pharmacol., 406, 265-271.
58. Sauzeau, V., Le Mellionnec, E., Bertoglio, J., Scalbert, E., Pacaud, P. & Loirand, G. (2001). Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ. Res., 88, 1102-1104.
59. Stirrat, A., Gallagher, M., Douglas, S.A., Ohlstein, E.H., Berry, C., Kirk, A., Richardson, M. & Maclean, M.R. (2001). Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am. J. Physiol., 280, H925-H928.
60. Takahashi, K., Totsune, K., Murakami, O. & Shibahara, S. (2001). Expression of urotensin II receptor mRNAs in various human tumour cell lines and secretion of urotensin II-like immunoreactivity by SW-13 adrenocortical carcinoma cells. Peptides, 22, 1175-1179.
61. Tal, M., Ammer, D.A., Karpuj, M., Krizhanovsky, V., Naim, M. & Thompson, D.A. (1995). A novel putative neuropeptide receptor expressed in neural tissue, including sensory epithelia. Biochem. Biophys. Res. Commun., 209, 752-759.
62. Totsune, K., Takahashi, K., Arihara, Z., Sone, M., Satoh, F., Ito, S., Hironobu, S. & Murakami, O. (2001). Role of urotensin II in patients on dialysis. Lancet, 358, 810-811.
63. Watanabe, T., Pakala, R., Katagiri, T. & Benedict, C.R. (2001a). Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation, 104, 16-18.
64. Watanabe, T., Pakala, R., Katagiri, T. & Benedict, C.R. (2001b). Synergistic effect of urotensin II with serotonin on vascular smooth muscle proliferation. J. Hypertens., 19, 2191-2196.
65. Weitzberg, E., Ahlborg, G. & Lundberg, J.M. (1991). Longlasting vasoconstriction and efficient regional extraction of endothelin-1 in human splanchnic and renal tissues. Biochem. Biophys. Res. Commun., 180, 1298-1303.
66. 2 receptors in the normal and failing human heart. J. Pharmacol. Exp. Therap., 284, 323-336.
67. Wilkinson, I.B., Affolter, J.T., De Haas, S.L., Pellegrini, M.P., Boyd, J., Winter, M.J., Balment, R.J. & Webb, D.J. (2002). High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. Cardiovasc. Res., 53, 341-347.
68. Winter, M.J., Hubbard, P.C., McCrohan, C.R. & Balment, R.J. (1999). A homologous radioimmunoassay for the measurement of urotensin II in the euryhaline flounder, Platichthys flesus. Gen. Comp. Endocrinol., 114, 249-256.
69. Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsui, Y., Yazaki, Y., Goto, K. & Masaki, T. (1988). A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature, 332, 411-415.
70. Zhang, Y.G., Li, J.X., Cao, J., Chen, J.J., Yang, J., Zhang, Z.K., Du, J.B. & Tang, C.S. (2002). Effect of chronic hypoxia on contents of urotensin II and its functional receptors in rat myocardium. Heart Vessels, 16, 64-68.
71. Zou, Y., Nagai, R. & Yamazaki, T. (2001). Urotensin-II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats. FEBS Lett., 508, 57-60.